56 search results for: mechanism of disease

Role <b>of</b> Type 2 Inflammation in Prurigo Nodularis Part 1: Overview <b>of</b> Type 2 Inflammation

expert video

Role of Type 2 Inflammation in Prurigo Nodularis Part 1: Overview of Type 2 Inflammation

8 min

Dermatology

Join Dr. Raj Chovatiya as he provides an overview of the impact of type 2 inflammation in prurigo nodularis in the first part of this discussion.

interactivity

Lung Function Decline: Why it Matters and What’s at Stake for Patients

5 min

Pulmonology

Understand the drivers of lung function decline in chronic obstructive pulmonary disease (COPD), including chronic inflammation, key risk factors, and the impact on patient well-being .

expert video

Under the Skin: Considerations for Atopic Dermatitis and Prurigo Nodularis in Clinical Practice

42 min

Dermatology

In this ADVENT symposium at the 2024 Diversity in Dermatology conference, experts Dr(s) Sarina Elmariah and Mona Shahriari engage in a dynamic discussion on diagnostic considerations for atopic dermatitis and prurigo nodularis and how clinical signs and itch in these diseases are impacted by type 2 inflammation.

expert video

Pathophysiology of Blister Formation in Bullous Pemphigoid

2 min

Dermatology

Professor Enno Schmidt discusses the pathophysiology of BP, focusing on the role of type 2 inflammation and blister formation

The Role <b>of</b> Mast Cells, Basophils, and Type 2 Cells and Cytokines in CSU

Infographic

The Role of Mast Cells, Basophils, and Type 2 Cells and Cytokines in CSU

5 min

Dermatology

The pathophysiology of chronic spontaneous urticaria (CSU) is complex and involves mast cell degranulation and elements of type 2 inflammation. Learn more about the role of mast cells, basophils, and type 2 inflammatory cells and cytokines involved in the pathophysiology of CSU.

interactivity

Skin Dyspigmentation In Prurigo Nodularis (PN)

10 min

Dermatology

This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.

interactivity

Skin Dyspigmentation In Prurigo Nodularis (PN)

10 min

Dermatology

This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.

expert video

Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU

9 min

Dermatology

Exploration of the shared type 2 inflammation and neuroimmune axis dysfunction in AD, PN, and CSU leading to itch.

IRS-ISIAN 2024 | The Importance <b>of</b> Understanding Smell Loss and Congestion in CRSwNP

expert video

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

15 min

Rhinology

Prof. Joaquim Mullol presents on the proposed mechanisms of smell loss and nasal congestion in CRSwNP.

expert video

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

60 min

Dermatology

This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

4 min

Dermatology

In this video soundbite from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson explains how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region